Patents by Inventor Kevin W. Moore
Kevin W. Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5985828Abstract: Receptor components for IL-10 are isolated and characterized. The amino acid sequence and nucleic acid encoding various species variants of the receptors are disclosed. Uses of the purified receptor gene and polypeptide are disclosed, including means for screening for agonists and antagonists of the receptor ligands, for producing diagnostic or therapeutic reagents, and for producing antibodies. Therapeutic or diagnostic reagents and kits are also provided.Type: GrantFiled: June 7, 1995Date of Patent: November 16, 1999Assignee: Schering CorporationInventors: Kevin W. Moore, Ying Liu, Alice Suk-Yue Ho, Di-Hwei Hsu, J. Fernando Bazan, Jimmy C. Tan, Chuan-Chu Chou
-
Patent number: 5976831Abstract: Soluble and membrane-bound forms of human Fc.gamma.RIII are provided, together with nucleic acids capable of encoding the same. Soluble Fc.gamma.RIIIs are useful in ameliorating the serum platelet deficiency associated with immune thrombocytopenic purpura. Cells expressing membrane-bound Fc.gamma.RIII are useful components in assays for serum immune complexes.Type: GrantFiled: April 5, 1995Date of Patent: November 2, 1999Assignee: Applied Research Systems ARS Holding, N.V.Inventors: Gary A. Peltz, Kevin W. Moore
-
Patent number: 5863796Abstract: Receptor components for IL-10 are isolated and characterized. The amino acid sequence and nucleic acid encoding various species variants of the receptors are disclosed. Uses of the purified receptor gene and polypeptide are disclosed, including means for screening for agonists and antagonists of the receptor ligands, for producing diagnostic or therapeutic reagents, and for producing antibodies. Therapeutic or diagnostic reagents and kits are also provided.Type: GrantFiled: June 7, 1995Date of Patent: January 26, 1999Assignee: Schering CorporationInventors: Kevin W. Moore, Ying Liu, Alice Suk-Yue Ho, Di-Hwei Hsu, J. Fernando Bazan, Jimmy C. Tan, Chuan-Chu Chou
-
Patent number: 5851801Abstract: Proteinaceous binding compositions are prepared employing hybrid DNA technology, where the variable region polypeptides of immunoglobulins are substantially reproduced to provide relatively small protein molecules having binding specificity and lacking the undesirable aspects of the heavy regions of immunoglobulins. The compositions find a wide range of use, particularly for physiological purposes for diagnosis and therapy. The binding compositions may be modified by labeling with radioisotopes, fluorescers, and toxins for specific applications in diagnosis or therapy.Type: GrantFiled: June 5, 1995Date of Patent: December 22, 1998Assignee: Schering CorporationInventors: Kevin W. Moore, Alejandro Zaffaroni
-
Patent number: 5840545Abstract: Proteinaceous binding compositions are prepared employing hybrid DNA technology, where the variable region polypeptides of immunoglobulins are substantially reproduced to provide relatively small protein molecules having binding specificity and lacking the undesirable aspects of the heavy regions of immunoglobulins. The compositions find a wide range of use, particularly for physiological purposes for diagnosis and therapy. The binding compositions may be modified by labeling with radioisotopes, fluorescers, and toxins for specific applications in diagnosis or therapy.Type: GrantFiled: June 5, 1995Date of Patent: November 24, 1998Assignee: Schering CorporationInventors: Kevin W. Moore, Alejandro Zaffaroni
-
Patent number: 5827513Abstract: Disclosed is a method for treating an individual who is predisposed to develop insulin-dependent diabetes mellitus. To practice the method, an amount of interleukin-10 protein effective to maintain blood glucose levels at a non-diabetic level is administered to an individual predisposed to develop the disease.Type: GrantFiled: March 30, 1995Date of Patent: October 27, 1998Assignee: Schering CorporationInventors: Martha W. Bond, Kevin W. Moore, Kenneth Pennline, Paulo J. M. Vieira
-
Patent number: 5789192Abstract: Receptor components for IL-10 are isolated and characterized. The amino acid sequence and nucleic acid encoding various species variants of the receptors are disclosed. Uses of the purified receptor gene and polypeptide are disclosed, including means for screening for agonists and antagonists of the receptor ligands, for producing diagnostic or therapeutic reagents, and for producing antibodies. Therapeutic or diagnostic reagents and kits are also provided.Type: GrantFiled: August 23, 1993Date of Patent: August 4, 1998Assignee: Schering CorporationInventors: Kevin W. Moore, Ying Liu, Alice Suk-Yue Ho, Di-Hwei Hsu, J. Fernando Bazan, Jimmy C. Tan, Chuan-Chu Chou
-
Patent number: 5776451Abstract: A method is provided for using interleukin-10 in adoptive immunotherapy of cancer. A population of tumor-infiltrating lymphocytes (TILs) are expanded in culture in the presence of interleukin-2 (IL-2) and interleukin-10 (IL-10). After administration of the TILs to a patient, effective amounts of both IL-2 and IL-10 are administered to enhance the tumor cell cytoxicity of the TILs and to reduce side effects caused by IL-2-induced cytokine production in the TILs and other cells of the patient.Type: GrantFiled: July 5, 1994Date of Patent: July 7, 1998Assignee: Schering CorporationInventors: Di-Hwei Hsu, Kevin W. Moore, Hergen Spits
-
Patent number: 5767077Abstract: Soluble and membrane-bound forms of human FC.gamma.RIII are provided, together with nucleic acids capable of encoding the same. Soluble Fc.gamma.RIIIs are useful in ameliorating the serum platelet deficiency associated with immune thrombocytopenic purpura. Cells expressing membrane-bound Fc.gamma.RIIIs are useful components in assays for serum immune complexes.Type: GrantFiled: June 7, 1995Date of Patent: June 16, 1998Assignee: Applied Research Systems ARS Holding N.V.Inventors: Gary A. Peltz, Kevin W. Moore
-
Patent number: 5756342Abstract: A method of treating EBV infections is provided. The method comprises administering an effective amount of an monoclonal antibody antagonist to the EBV protein, BCRF1. Preferably, the antagonist is a blocking monoclonal antibody specific for BCRF1, or a fragment or binding composition derived therefrom.Type: GrantFiled: June 5, 1995Date of Patent: May 26, 1998Assignee: Schering CorporationInventor: Kevin W. Moore
-
Patent number: 5736390Abstract: BCRF1 proteins are provided for treating conditions associated with excessive production of IFN-.gamma.. Also provided are expression vectors for producing BCRF1 proteins. Compositions of the invention are useful in treating a variety of disorders, including allergy, psoriasis, tissue rejection, and MHC-linked autoimmune diseases.Type: GrantFiled: June 6, 1995Date of Patent: April 7, 1998Assignee: Schering CorporationInventors: Kevin W. Moore, Robert A. Kastelein
-
Patent number: 5716804Abstract: Amino acid sequence and nucleic acid encoding various functional variants of the IL-10 receptors. Uses of the receptor gene and polypeptides are disclosed, including means for screening for agonists and antagonists of the receptor ligands, for producing diagnostic or therapeutic reagents, and for producing antibodies. Therapeutic or diagnostic reagents and kits are also provided.Type: GrantFiled: April 19, 1995Date of Patent: February 10, 1998Assignee: Schering CorporationInventors: Kevin W. Moore, Sherry Wei, Alice Suk-Yue Ho
-
Patent number: 5627155Abstract: BCRF1 proteins are provided for treating conditions associated with excessive production of IFN-.gamma.. Also provided are expression vectors for producing BCRF1 proteins. Compositions of the invention are useful in treating a variety of disorders, including allergy, psoriasis, tissue rejection, and MHC-linked autoimmune diseases.Type: GrantFiled: May 26, 1995Date of Patent: May 6, 1997Assignee: Schering CorporationInventors: Kevin W. Moore, Robert A. Kastelein
-
Patent number: 5618812Abstract: Compounds of Formula (I), and salts and prodrugs thereof, wherein R.sup.1 represents H, optionally substituted C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl; R.sup.2 is NHR.sup.12 or (CH.sub.2).sub.s R.sup.13 where 5 is 0, 1 or 2; R.sup.3 represents C.sub.1-6 alkyl, halo or NR.sup.6 R.sup.7 ; R.sup.4 and R.sup.5 are H, C.sub.1-12 alkyl optionally substituted by NR.sup.9 R.sup.9' or an azacyclic or azabicyclic group, optionally substituted C.sub.4-9 cycloalkyl, C.sub.4-9 cycloalkyl C.sub.1-4 alkyl, aryl, arylC.sub.1-6 alkyl or azacyclic or azabicyclic groups, or R.sup.4 and R.sup.5 together form the residue of an optionally substituted azacyclic or azabicyclic ring system; x is 0, 1, 2 or 3; R.sup.12 is optionally substituted phenyl or pyridyl; R.sup.13 represents a group (A) wherein R.sup.14 is H or C.sub.1-6 alkyl; R.sup.15 is H, C.sub.1-6 alkyl, halo or NR.sup.6 R.sup.7 ; and the dotted line is an optional covalent bond; are CCK and/or gastrin antagonists useful in therapy.Type: GrantFiled: January 26, 1995Date of Patent: April 8, 1997Assignee: Merck Sharp & Dohme, Ltd.Inventors: Jose L. Castro Pineiro, William R. Carling, Mark S. Chambers, Stephen R. Fletcher, Sarah C. Hobbs, Victor G. Matassa, Kevin W. Moore, Graham A. Showell, Michael G. Russell
-
Patent number: 5614532Abstract: A class of 2-(1H)-quinolone derivatives, substituted at the 3-position by an optionally substituted aryl substituent, are selective non-competitive antagonists of NMDA receptors and/or are antagonists of AMPA receptors, and are therefore of utility in the treatment of conditions, such as neurodegenerative disorders, convulsions or schizophrenia, which require the administration of an NMDA and/or AMPA receptor antagonist.Type: GrantFiled: May 25, 1994Date of Patent: March 25, 1997Assignee: Merck, Sharp & Dohme Ltd.Inventors: William R. Carling, Paul D. Leeson, Michael Rowley, Kevin W. Moore
-
Patent number: 5252584Abstract: A class of 4-hydroxy-2(1H)-quinolone derivatives, substituted at the 3-position by an N-linked heteroaromatic ring system, are selective non-competitive antagonists of NMDA receptors and/or are antagonists of AMPA receptors, and are therefore of utility in the treatment of conditions, such as neurodegenerative disorders, convulsions or schizophrenia, which require the administration of an NMDA and or AMPA receptor antagonist.Type: GrantFiled: December 3, 1991Date of Patent: October 12, 1993Assignee: Merck Sharp & Dohme LimitedInventors: William R. Carling, Paul D. Leeson, Kevin W. Moore
-
Patent number: 5231012Abstract: Mammalian genes and proteins, designated cytokine synthesis inhibitory factors (CSIFs) (now known as interleukin -10), are provided which are capable of inhibiting the synthesis of cytokines associated with delayed type hypersensitivity responses, and which, together with antagonists, are useful in treating diseases associated with cytokine imbalances, such as leishmaniasis and other parasitic infections, and certain immune disorders including MHC associated autoimmune diseases caused by excessive production of interferon-.gamma..Type: GrantFiled: July 20, 1992Date of Patent: July 27, 1993Assignee: Schering CorporationInventors: Timothy R. Mosmann, Kevin W. Moore, Martha W. Bond, Paulo J. M. Vieira
-
Patent number: 4758511Abstract: Plasmid vectors are provided that carry complementary DNA (cDNA) clones coding for polypeptides exhibiting mammalian IgE binding factor activity. One of these clones contains an open reading frame consisting of 556 codons. The cDNA is derived from messenger RNA isolated from a rat/mouse T-cell hybridoma line. The cDNA was cloned by incorporation into a pcD plasmid vector. The plasmid vector also contains DNA segments from the SV40 virus, permitting expression of the cDNA to form a polypeptide having IgE potentiating activity after transfection into a mammalian host cell, such as monkey Cos7 cells.Type: GrantFiled: March 16, 1984Date of Patent: July 19, 1988Assignees: DNAX Research Institute of Molecular and Cellular Biology, Inc., The Johns Hopkins UniversityInventors: Christine L. Martens, Kevin W. Moore, Kimishige Ishizaka, Thomas F. Huff
-
Patent number: 4749685Abstract: Immunosuppressive peptides having glycosylation inhibiting factor activity are provided.Type: GrantFiled: August 1, 1986Date of Patent: June 7, 1988Assignee: DNAX Research Institute of Molecular and Cellular Biology, Inc.Inventors: Christine L. Martens, Kevin W. Moore
-
Patent number: 4642334Abstract: Proteinaceous binding compositions are prepared employing hybrid DNA techogy, where the variable region polypeptides of immunoglobulins are substantially reproduced to provide relatively small protein molecules having binding specificity and lacking the undesirable aspects of the heavy regions of immunoglobulins. The compositions find a wide range of use, particularly for physiological purposes for diagnosis and therapy. The binding compositions may be modified by labeling with radioisotopes, fluorescers, and toxins for specific applications in diagnosis or therapy.Type: GrantFiled: December 5, 1983Date of Patent: February 10, 1987Assignee: DNAX Research Institute of Molecular and Cellular Biology, Inc.Inventors: Kevin W. Moore, Alejandro Zaffaroni